{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=86",
    "query": {
      "condition": "Phase I",
      "page": 86
    },
    "page_size": 10
  },
  "pagination": {
    "page": 86,
    "page_size": 10,
    "total_count": 18752,
    "total_pages": 1876,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=87&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=85&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T18:59:01.131Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02627443",
      "title": "Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Fallopian Tube Carcinoma",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Primary Peritoneal Carcinoma",
        "Ovarian Endometrioid Tumor",
        "Ovarian High Grade Serous Adenocarcinoma",
        "Platinum-Sensitive Ovarian Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2017-05-16",
      "completion_date": "2027-06-03",
      "has_results": true,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02627443"
    },
    {
      "nct_id": "NCT00710125",
      "title": "Safety Study of GPX-150 in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors - Phase 1 Population"
      ],
      "interventions": [
        {
          "name": "GPX-150 for Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gem Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2008-01",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2014-08-05",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00710125"
    },
    {
      "nct_id": "NCT06066138",
      "title": "A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Alveolar Soft Part Sarcoma",
        "Metastatic Alveolar Soft Part Sarcoma",
        "Locally Advanced Non Small Cell Lung Cancer",
        "Metastatic Non Small Cell Lung Cancer",
        "Locally Advanced Small Cell Lung Cancer",
        "Metastatic Small Cell Lung Cancer",
        "Locally Advanced Hepatocellular Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Locally Advanced Melanoma",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-11-04",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06066138"
    },
    {
      "nct_id": "NCT04694638",
      "title": "Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prone Positioning",
        "Covid19",
        "Hypoxemic Respiratory Failure",
        "ARDS",
        "Non Invasive Ventilation",
        "High Flow Nasal Cannulla"
      ],
      "interventions": [
        {
          "name": "Body position change",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 6,
      "start_date": "2020-05-21",
      "completion_date": "2023-05-10",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04694638"
    },
    {
      "nct_id": "NCT00610948",
      "title": "Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "panitumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2008-03",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2017-05-04",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00610948"
    },
    {
      "nct_id": "NCT05025085",
      "title": "A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "AGEN1777",
          "type": "DRUG"
        },
        {
          "name": "a PD-1 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-10-04",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 11,
      "location_summary": "Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Southfield",
          "state": "Michigan"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05025085"
    },
    {
      "nct_id": "NCT04309643",
      "title": "Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "CTP-543",
          "type": "DRUG"
        },
        {
          "name": "Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Concert Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2020-06-09",
      "completion_date": "2020-07-08",
      "has_results": false,
      "last_update_posted_date": "2020-07-16",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04309643"
    },
    {
      "nct_id": "NCT02150525",
      "title": "Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ductal Breast Carcinoma in Situ",
        "Breast Cancer, Stage I",
        "Breast Cancer, Stage II",
        "Breast Cancer, Stage III"
      ],
      "interventions": [
        {
          "name": "omega-3 fatty acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire administration",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 65 Years · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2010-08",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02150525"
    },
    {
      "nct_id": "NCT01311076",
      "title": "TAK-329 Glucose Clamp Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "TAK-329",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 37,
      "start_date": "2011-03",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-02-13",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01311076"
    },
    {
      "nct_id": "NCT01155817",
      "title": "Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bone Marrow Transplant Failure",
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, T-Cell, Peripheral"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2010-08",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2020-04-15",
      "last_synced_at": "2026-11-12T18:59:01.131Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Denver, Colorado • Buffalo, New York + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01155817"
    }
  ]
}